Keyhole limpet hemocyanin: an effective adjunct against melanoma in vivo.
Am J Surg
; 194(5): 628-32, 2007 Nov.
Article
em En
| MEDLINE
| ID: mdl-17936425
ABSTRACT
BACKGROUND:
We have previously demonstrated the potent in vitro antiproliferative effects of keyhole limpet hemocyanin (KLH) against melanoma. Our prior studies directed us to hypothesize that KLH would be effective in vivo against melanoma, alone and in combination with conventional immunotherapy.METHODS:
Mice were inoculated with 2 x 10(7) HTB68 cells and randomized to 6 groups. Treatment groups consisted of control, KLH 200 microg, alpha interferon (AIFN) 1000 IU, interleukin-2 (IL-2) 5000 IU, KLH + AIFN, and KLH + IL-2.RESULTS:
KLH + IL-2 exhibited the greatest reduction in tumor volume (30%) as compared to control (P = .014), followed by KLH + AIFN (28%, P = .031). Singly treated animals had less tumor inhibition IL-2 (30%, P = .022), KLH (18%, not significant), and AIFN (16%, not significant).CONCLUSIONS:
KLH augments the effects of AIFN, one of the standard immunotherapeutic agents against melanoma in vivo. Further in vivo and early clinical studies into the effects of KLH as both a single and combined agent are warranted.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Hemocianinas
/
Adjuvantes Imunológicos
/
Melanoma
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Am J Surg
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Estados Unidos